Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01117025 · ClinicalTrials.gov registry record · Phase 2
Combined Treatment of Resistant Hypertension and Atrial Fibrillation
A Phase 2 study, sponsored by Meshalkin Research Institute of Pathology of Circulation.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT01117025 is a Phase 2 study that has completed, run by Meshalkin Research Institute of Pathology of Circulation. The registered enrollment target is 26 participants.
The verdict
NCT01117025, a Phase 2 study, has completed, sponsored by Meshalkin Research Institute of Pathology of Circulation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is the comparative evaluation of systolic blood pressure (SBP) lowering, atrial fibrillation (AF) recurrence and clinical data in patients with paroxysmal/persistent AF and resistant hypertension, undergoing AF ablation alone or combined with percutaneous renal denervation.
Interventions
- PROCEDURE Circumferential PV isolation
- PROCEDURE Circumferential PVI+renal denervation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01117025
The ClinicalTrials.gov registry entry for NCT01117025 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meshalkin Research Institute of Pathology of Circulation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Circumferential PV isolation is the first listed.
NCT01117025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01117025 about?
NCT01117025 is a clinical study titled "Combined Treatment of Resistant Hypertension and Atrial Fibrillation". The purpose of this study is the comparative evaluation of systolic blood pressure (SBP) lowering, atrial fibrillation (AF) recurrence and clinical data in patients with paroxysmal/persistent AF and resistant hypertension, undergoing AF ablation alone or combined with percutaneous renal denervation.
What is the current status of trial NCT01117025?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2010-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01117025?
The interventions under investigation include: Circumferential PV isolation (PROCEDURE), Circumferential PVI+renal denervation (PROCEDURE).
Who is sponsoring clinical trial NCT01117025?
This trial is sponsored by Meshalkin Research Institute of Pathology of Circulation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.